3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2011 Results
SHENYANG, China, Feb. 3, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited fourth quarter and full year 2011 results after the NASDAQ stock market closes on Thursday, March 8, 2012 at 8:00pm (US Eastern).
Following the earnings announcement, 3SBio's senior management will host a conference call on Friday, March 9, 2012 at 5:00am (US Pacific) / 8:00am (US Eastern) / 9:00pm (Beijing) to discuss its unaudited fourth quarter and full year 2011 results and recent business activity. The conference call may be accessed using the dial-in numbers below:
Conference ID: 50023809
China landline: 800-819-0121
China mobile: 400-620-8038
Hong Kong : 852-2475-0994
United States: 718-354-1231
International toll-free dial-in:
Hong Kong: 800930346
United States: 1-866-519-4004
United Kingdom: 080-8234-6646
International toll dial-in: 65 6723 9381
Replay- Conference ID: 50023809
A telephone replay will be available two hours after the call until March 17, 2012 at:
United States: 1-866-214-5335
A replay of the webcast will be available within one hour after the conclusion of the call.
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.
Chief Financial Officer
Tel: + 86 24 2581-1820
Director of Investor Relations
Tel: + 852 8191-6991
SOURCE 3SBio Inc.
More by this Source
3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
Oct 29, 2013, 06:09 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.